CompanyGraph
Asymchem Laboratories (Tianjin) Co., Ltd.
002821 · SZSE · China
asymchem.com.cnFinancials as of FY2025
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $9.77B, above the global median of $1.18B
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.71%Below 5Y avg (1.17%)
Annual Rate
CNY 1.30Paid annual
Payout Ratio
35.4%Sustainable
Last Ex-Dividend
Jun 26, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
65.81BCNY9.77B · vs all stocks (USD)
Trailing P/E
60.53xvs Biotechnology peers
Revenue (TTM)
6.93BCNY1.03B · vs all stocks (USD)
Profit Margin
16.02%vs Biotechnology peers
Beta
0.1180xvs all stocks
52-Week Change
71.90%vs all stocks
Market Capitalization
65.81BCNY9.77B · vs all stocks (USD)
Enterprise Value
54.30BCNY8.07B · vs all stocks (USD)
Trailing P/E
60.53xvs Biotechnology peers
Forward P/E
37.46xvs Biotechnology peers
PEG Ratio
-10.77xvs Biotechnology peers
Price to Sales (TTM)
9.77xvs Biotechnology peers
Price to Book (MRQ)
3.79xvs Biotechnology peers
Enterprise to Revenue
7.83xvs Biotechnology peers
Enterprise to EBITDA
32.62xvs Biotechnology peers
Gross Margin
43.02%vs Biotechnology peers
Profit Margin
16.02%vs Biotechnology peers
Operating Margin
22.27%vs Biotechnology peers
Return on Assets (TTM)
3.64%vs Biotechnology peers
Return on Equity (TTM)
6.28%vs Biotechnology peers
Revenue (TTM)
6.93BCNY1.03B · vs all stocks (USD)
Revenue per Share (TTM)
19.40CNYUpdated Aug 20, 2026Quarterly Revenue Growth
16.90%vs Biotechnology peers
Gross Profit (TTM)
2.86BCNY425.09M · vs all stocks (USD)
EBITDA (TTM)
1.96BCNY291.31M · vs all stocks (USD)
Net Income (TTM)
1.11BCNY164.90M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-6.80%vs Biotechnology peers
Operating Cash Flow (TTM)
1.48BCNY220.54M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-180.19MCNY-26.76M · vs all stocks (USD)
Trailing Annual Dividend Rate
1.30CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
0.71%vs all stocks
5-Year Average Dividend Yield
1.17%vs all stocks
Payout Ratio
35.37%vs Biotechnology peers
Minority Interest (Equity)
11.04MCNYFY2025 · Dec 31, 2025Revenue
6.67BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
3.87BCNYFY2025 · Dec 31, 2025Gross Profit
2.80BCNYFY2025 · Dec 31, 2025Operating Income
1.25BCNY186.26M · vs all stocks (USD)
Pre-tax Income
1.29BCNYFY2025 · Dec 31, 2025Income Tax Expense
159.74MCNYFY2025 · Dec 31, 2025Net Income
1.13BCNYFY2025 · Dec 31, 2025EBIT
1.30BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.96BCNYFY2025 · Dec 31, 2025Research & Development
593.26MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
260.93MCNYFY2025 · Dec 31, 2025Other Operating Expenses
63.39MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
202.97MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
12.75MCNYFY2025 · Dec 31, 2025EPS (Basic)
3.16CNYFY2025 · Dec 31, 2025EPS (Diluted)
3.16CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
358.41MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
358.41MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
1.13BCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
5.93MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
518.17MCNYFY2025 · Dec 31, 2025Free Cash Flow
-752.15MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
3.40BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
1.13BCNYFY2025 · Dec 31, 2025Other Non-cash Items
43.20MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-265.55MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-386.11MCNYFY2025 · Dec 31, 2025Capital Expenditures
-1.27BCNYFY2025 · Dec 31, 2025Purchase of Investments
-11.53BCNYFY2025 · Dec 31, 2025Sale of Investments
12.15BCNYFY2025 · Dec 31, 2025Other Investing Activity
14.16MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-633.20MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-395.07MCNYFY2025 · Dec 31, 2025Other Financing Charges
50.23MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-344.83MCNYFY2025 · Dec 31, 2025Shares Outstanding
360.87MSharesUpdated Aug 20, 2026Float Shares
221.34MSharesUpdated Aug 20, 2026% Held by Insiders
42.10%vs all stocks
% Held by Institutions
22.08%vs all stocks
Total Cash (MRQ)
7.80BCNY1.16B · vs all stocks (USD)
Total Cash per Share (MRQ)
21.53CNYUpdated Aug 20, 2026Total Debt (MRQ)
293.09MCNY43.53M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0163xvs Biotechnology peers
Current Ratio (MRQ)
5.69xvs Biotechnology peers
Book Value per Share (MRQ)
49.55CNYUpdated Aug 20, 2026Total Assets
20.28BCNY3.01B · vs all stocks (USD)
Total Current Assets
11.51BCNYFY2025 · Dec 31, 2025Total Liabilities
2.63BCNYFY2025 · Dec 31, 2025Total Non-current Assets
8.77BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
662.84MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.97BCNYFY2025 · Dec 31, 2025Cash
5.78BCNYFY2025 · Dec 31, 2025Cash Equivalents
543.99MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
6.32BCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.12BCNYFY2025 · Dec 31, 2025Accounts Receivable
1.95BCNYFY2025 · Dec 31, 2025Inventory
1.47BCNYFY2025 · Dec 31, 2025Accounts Payable
589.04MCNYFY2025 · Dec 31, 2025Short-term Debt
52.71MCNYFY2025 · Dec 31, 2025Other Current Liabilities
26.95KCNYFY2025 · Dec 31, 2025Long-term Debt
256.47MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
27.56KCNYFY2025 · Dec 31, 2025Common Stock (Book)
360.56MCNYFY2025 · Dec 31, 2025Retained Earnings
8.82BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
17.65BCNY2.62B · vs all stocks (USD)
Treasury Stock
838.45MCNYFY2025 · Dec 31, 202552-Week Low
88.46CNYUpdated Aug 20, 202652-Week High
200.00CNYUpdated Aug 20, 202652-Week Change
71.90%vs all stocks
Beta
0.1180xvs all stocks
50-Day MA
155.70CNYUpdated Aug 20, 2026200-Day MA
117.69CNYUpdated Aug 20, 2026Avg 10-Day Volume
16.37MSharesUpdated Aug 20, 2026Avg 30-Day Volume
13.71MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
3.10CNYUpdated Aug 20, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock valued?
Down-Close Streak With Profitability
A run of down weeks on a company profitable three years running and funded by equity.
Reads
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $9.77B, above the global median of $1.18BNotable
Market cap (USD): 9,773,573,258.926Global Median: 1,179,398,897.704
Revenue is $1.03B, above the global median of $534.05MNotable
Revenue (USD): 1,029,364,412.109Global Median: 534,052,387.958
Companies that share the same coordination system — how they create, deliver, or capture value.
Nuvalent, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Fosun Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Kymera Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Protagonist Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Insulet Corporation
Tier 1ProductionApproval-Gated PipelineRule
Masimo Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Laurus Labs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aurobindo Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Abivax SA
Tier 1ProductionApproval-Gated PipelineRule
Apogee Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Havells India Ltd.
2 interpretationsDown-Close Streak With ProfitabilityHigh Retained Earnings With Profitability And Equity
UFP Industries, Inc.
2 interpretationsDown-Close Streak With ProfitabilityHigh Retained Earnings With Profitability And Equity
Amoy Diagnostics Co., Ltd.
2 interpretationsDown-Close Streak With ProfitabilityHigh Retained Earnings With Profitability And Equity